E Thomas Corcoran

Director E Thomas Corcoran buys 10,000 PAHC shares at $31.77; stock now $28.52, -52.5% from 52-week high

E Thomas Corcoran, a PAHC director, purchased 10,000 shares at $31.77 on 2026-05-29, increasing his holdings to 41,459 shares (a 31.8% increase). The transaction occurs against a backdrop of significant recent weakness: the stock trades at $28.52, down 52.5% from its 52-week high of $60.08 and down 48.0% over the past 30 days. Corcoran's prior two purchases at PAHC both posted positive 90-day returns (5.2% and 16.2%), suggesting his historical timing at this ticker has been favorable. The company's underlying fundamentals remain solid—revenue of $383.5M, net income of $24.0M, annual revenue growth of 27.4%, and a P/E of 20.67—yet the stock's sharp recent decline stands in stark contrast. This purchase represents an open-market commitment of capital during a period of substantial drawdown, though whether it reflects conviction or represents a discretionary tactical move cannot be determined from the transaction data alone.

Director E. Thomas Corcoran purchases 5,000 shares of PAHC at $22.10; holdings rise to 30,000 shares.

Director E. Thomas Corcoran acquired 5,000 shares at $22.10, expanding his holdings by 20.0% from 25,000 to 30,000 shares. His prior open-market purchase at PAHC on 2024-09-04 showed a 90-day return of +16.2%, demonstrating a pattern of well-timed acquisitions at this ticker. The current price of $22.25 is -15.1% from the 52-week high, positioning this purchase in a modestly depressed region of the stock's recent range. With a P/E of 79.46 and net income of $3.2M against revenue of $309.3M, the company operates with thin profitability margins, a structural constraint to monitor alongside the insider's repeated commitment to accumulate position.

PAHC Director E. Thomas Corcoran purchases 5,000 shares at $20.02; holdings rise to 25,000 shares (+25.0%)

Director E. Thomas Corcoran purchased 5,000 shares (5.0K shares) of PAHC at $20.02 on 2024-09-04, increasing his holdings to 25,000 shares (25.0K shares), a net change of +25.0% versus pre-transaction holdings. The stock has since declined 9.4% from its 52-week high of $21.47, though it rose 14.5% over the past 30 days and 13.4% over 90 days, indicating recent momentum. The company carries a notably elevated P/E of 324.33 relative to its $8.4M net income on $263.2M quarterly revenue, reflecting thin profitability despite modest revenue growth of 4.1% year-over-year. This purchase adds to a modest equity stake that remains small relative to the company's $1.3B market cap, warranting observation of whether this reflects management confidence in near-term operational or strategic developments.